Wednesday July 29th 2020

Tags

Category

With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.

The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy clients, while the expanded Boston office will allow Biocair to improve delivery and service, with greater operational capacity.

Bruce Kennedy, Chief Commercial Officer, stated, “Biocair has always been strong in the US market, with offices in Los Angeles, New York, Raleigh Durham, San Diego, San Francisco and Washington as well as Boston and Philadelphia. Now, our new premises spearhead our goal of delivering industry-leading specialist logistics services for the life sciences across the US and beyond.”

At a time when some logistics companies are under pressure to meet the transport requirements of time and temperature-sensitive biological materials due to COVID-19, Biocair has maintained and enhanced its customer-centric approach, with superlative customer service and rapid response protocols, ensuring its customers are at the heart of an outstanding logistical service offering.

From temperature-controlled vehicles through to an expanding cryogenic service station network, Biocair is committed to supply chain excellence. Please contact your local office for more information about Biocair’s services.

About Biocair

Biocair is a specialist courier with over 30 years of dedicated experience in the pharmaceutical, biotechnology and life science sectors. The company has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance amongst others. Biocair focuses on providing the most comprehensive service options available whilst delivering flexible, tailored, cost effective logistics solutions to all clients.

Biocair operates across Europe, Africa, Asia and the Americas.